Table 1 Baseline main demographic and clinical characteristics.

From: Effectiveness and safety of XEN45 implant over 12 months of follow-up: data from the XEN-Glaucoma Treatment Registry

 

Total (n = 239)

XEN (n = 144)

XEN+Phaco (n = 95)

P

Age, median (IQR)

72.0 (65.0–78.0)

73.0 (62.0–79.0)

72.0 (68.0–76.5)

0.54

Gender Female

106 (44.3%)

67 (46.5%)

39 (41.0%)

0.48

Ethnicity

  Caucasian

239 (100.0%)

144 (100.0%)

95 (100.0%)

–

BCVA, median (IQR)

0.5 (0.2–0.8)

0.7 (0.4–0.9)

0.4 (0.1–0.6)

<0.001

IOP, median (IQR)

23.0 (20.0–26.0)

24.0 (20.7–26.0)

23.0 (20.0–26.0)

0.28

N of OHMs, median (IQR)

3.0 (2.0–3.0)

3.0 (2.0–3.0)

3.0 (2.0–3.0)

0.06

Type of Glaucoma

    

0.29

  POAG

219 (91.6%)

133 (92.3%)

86 (90.5%)

 

  PXFG

16 (6.7%)

8 (5.5%)

8 (8.4%)

 

  Steroid induced

3 (1.2%)

3 (2.0%)

–

 

  Not reported

1 (0.4%)

–

1 (1.0%)

 

Lens Status

    

<0.001

  Phakic

130 (54.4%)

35 (24.3%)

95 (100.0%)

 

  Pseudo-phakic

109 (45.6%)

109 (75.7%)

–

 

Previous Procedures

    

<0.001

  None

124 (51.8%)

33 (22.9%)

94 (98.9%)

 

  Phaco

109 (45.6%)

109 (75.7%)

–

 

  SLT/ALTa

5 (2.1%)

4 (2.7%)

1 (1.0%)

 

  Other

4 (1.6%)

4 (2.7%)

–

 

MD (dB), median (IQR)

−11.0 (−18.0 to −5.2)

−12.0 (−18.0 to −6.0)

−10.0 (−16.0 to −5.0)

0.22

VF Severity

    

0.19

  Better than −6 dB

56 (23.4%)

32 (22.2%)

24 (25.3%)

 

  −6 to −12 dB

63 (26.4%)

32 (22.2%)

31 (32.6%)

 

  Worse than −12 dB

103 (43.1%)

67 (46.6%)

36 (37.9%)

 

  Not reported

17 (7.1%)

13 (9.0%)

4 (4.2%)

 

C/D Ratio, median (IQR)

0.7 (0.6–0.8)

0.7 (0.6–0.8)

0.7 (0.6–0.8)

0.46

Position of the Surgeon

    

0.06

  Superior

161 (67.3%)

104 (72.2%)

57 (60.0%)

 

  Temporal

78 (32.6%)

40 (27.7%)

38 (40.0%)

 

Position of the XEN45 implant

    

<0.001

  Superior-nasal

217 (90.8%)

129 (89.6%)

88 (92.6%)

 

  Superior-temporal

4 (1.6%)

4 (2.7%)

0 (0.0%)

 

  Superior

4 (1.7%)

1 (0.7%)

3 (3.2%)

 

  Nasal

11 (4.6%)

9 (6.2%)

2 (2.0%)

 

  Temporal

1 (0.4%)

0 (0.0%)

1 (1.0%)

 

  Not reported

2 (0.8%)

1 (0.7%)

1 (1.0%)

Viscoelastic type

    

<0.001

  Cohesive

213 (89.1%)

122 (84.7%)

91 (95.8%)

 

  Dispersive

26 (10.9%)

22 (15.3%)

4 (4.2%)

 
  1. Categorical variables are reported as proportions and comparisons were made using a Fisher exact test. Continuous variables are reported in medians (interquartile range [IQR]) and compared with Wilcoxon test.
  2. BCVA Best corrected visual acuity, IOP Intraocular pressure, OHMs ocular hypotensive medications, POAG primary open angle glaucoma, PXFG pseudoexfoliation glaucoma, PACG primary angle closure glaucoma, SLT selective laser trabeculoplasty, ALT Argon laser trabeculoplasty, MD Mean Deviation, VF Visual field, C/D Cup to Disc.
  3. aPerformed as standalone procedure or in patients with history of previous procedures.
Back to article page